Total Valuation
Celltrion Pharm Inc. has a market cap or net worth of ₩1.68T. The enterprise value is ―.
Market Cap₩1.68T
Enterprise Value―
Share Statistics
Celltrion Pharm Inc. has 43,683,804 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,683,804
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Celltrion Pharm Inc.’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 7.05%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)7.05%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee10.00T>
Profits Per Employee10.00T>
Employee Count―
Asset Turnover0.71
Inventory Turnover3.03
Valuation Ratios
The current PE Ratio of Celltrion Pharm Inc. is 44.1. Celltrion Pharm Inc.’s PEG ratio is 1.21.
PE Ratio44.1
PS Ratio6.37
PB Ratio7.83
Price to Fair Value7.83
Price to FCF49.85
Price to Operating Cash Flow23.00
PEG Ratio1.21
Income Statement
In the last 12 months, Celltrion Pharm Inc. had revenue of 536.40B and earned 38.75B in profits. Earnings per share was 874.91.
Revenue536.40B
Gross Profit163.78B
Operating Income56.09B
Pretax Income49.71B
Net Income38.75B
EBITDA78.63B
Earnings Per Share (EPS)874.91
Cash Flow
In the last 12 months, operating cash flow was 86.43B and capital expenditures -17.92B, giving a free cash flow of 68.51B billion.
Operating Cash Flow86.43B
Free Cash Flow68.51B
Free Cash Flow per Share1.57K
Dividends & Yields
Celltrion Pharm Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.43
52-Week Price Change-20.43%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)84.42K
Important Dates
Celltrion Pharm Inc. upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Celltrion Pharm Inc. as a current ratio of 1.66, with Debt / Equity ratio of 36.93%
Current Ratio1.66
Quick Ratio1.23
Debt to Market Cap0.04
Net Debt to EBITDA1.42
Interest Coverage Ratio8.41
Taxes
In the past 12 months, Celltrion Pharm Inc. has paid 10.96B in taxes.
Income Tax10.96B
Effective Tax Rate0.22
Enterprise Valuation
Celltrion Pharm Inc. EV to EBITDA ratio is 44.85, with an EV/FCF ratio of 51.47.
EV to Sales6.57
EV to EBITDA44.85
EV to Free Cash Flow51.47
EV to Operating Cash Flow40.80
Balance Sheet
Celltrion Pharm Inc. has ₩116.93B in cash and marketable securities with ₩161.31B in debt, giving a net cash position of -₩44.39B billion.
Cash & Marketable Securities₩116.93B
Total Debt₩161.31B
Net Cash-₩44.39B
Net Cash Per Share-₩1.02K
Tangible Book Value Per Share₩8.87K
Margins
Gross margin is 29.75%, with operating margin of 10.46%, and net profit margin of 7.22%.
Gross Margin29.75%
Operating Margin10.46%
Pretax Margin9.27%
Net Profit Margin7.22%
EBITDA Margin14.66%
EBIT Margin10.51%
Analyst Forecast
The average price target for Celltrion Pharm Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast12.69%
EPS Growth Forecast45.38%